We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Drug cartel

2 February 2007 By Pierre Briancon

Given the huge synergies on offer, the French group could afford to pay 20% on top of an inflated price and still create a bit of value. But Sanofi’s boss doesn’t like excessive leverage and the BMS shareholders may not be too enamoured of French paper.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)